Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

BACKGROUND: Despite recent advances, there is an urgent need for agents targeting HER2-expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a dendritic cell (DC) vaccine targeting HER2 in patients with metastatic cancer or bladder cancer at high risk of relapse. PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeng, Hoyoung M., Moore, Brittni N., Bagheri, Hadi, Steinberg, Seth M., Inglefield, Jon, Dunham, Kim, Wei, Wei-Zen, Morris, John C., Terabe, Masaki, England, Lee C., Roberson, Brenda, Rosing, Douglas, Sachdev, Vandana, Pack, Svetlana D., Miettinen, Markku M., Barr, Frederic G., Weiner, Louis M., Panch, Sandhya, Stroncek, David F., Wood, Lauren V., Berzofsky, Jay A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716407/
https://www.ncbi.nlm.nih.gov/pubmed/34976830
http://dx.doi.org/10.3389/fonc.2021.789078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716407/
https://www.ncbi.nlm.nih.gov/pubmed/34976830
http://dx.doi.org/10.3389/fonc.2021.789078

Ejemplares similares